Background
==========

Infections of the central nervous system (CNS) are potentially life threatening, requiring rapid diagnosis and immediate parenteral treatment. Nearly one in four adults with acute bacterial meningitis will die and many survivors sustain neurological deficits. Patient outcomes have not changed since the early 1960s, despite the introduction of potent antibiotics and specialized intensive care units \[[@B1]\]. Many infectious agents reach the CNS by hematogenous spread \[[@B2]\]. Pneumococcal infection may also arise from chronic infection of the paranasal sinuses and or middle ear. Furthermore, organisms present in the nasopharyx may reach the CNS directly, if the dura mater is damaged in some way following head injury or surgery \[[@B2]\]. Bacterial pathogens isolated from the CNS in patients with symptoms and diagnostic signs of bacterial meningitis are *Streptococcus pneumoniae*, *Streptococcus agalactiae*and other gram-positive cocci, *Haemophilus influenzae*, *Neisseria meningitidis*, and *Escherichia coli*\[[@B3],[@B4]\]. The epidemiology of infectious agent varies with patient age and history of immunization against *Haemophilus influenzae*type b, meningococcus and pneumococcus. *N. meningitidis*is now the most common cause of meningitis in young people with a peak incidence at 6 months age coinciding with the loss of maternal antibody protection \[[@B5]\], whilst pneumococcal meningitis is the most common bacterial meningitis in middle-aged and elderly patients \[[@B3],[@B4]\].

The need to treat infections of the CNS immediately requires empiric choice of an antibacterial agent. For many years β-lactams have comprised the cornerstone of therapy and parenteral third-generation cephalosporins such as ceftriaxone or cefotaxime are most commonly used \[[@B6]\]. Where infection is likely to have occurred from another body site, available laboratory information on identification and antibiogram of the organism can help target therapy appropriately. The emergence of antibiotic resistance in *S. pneumoniae*, *Staphylococcus aureus*, and enteric gram-negative bacilli documents the need for susceptibility testing to ensure appropriate antimicrobial chemotherapy. In contrast to community respiratory infections, for which antimicrobial susceptibility surveillance studies are frequently published, few data are available to provide a current perspective on the relative incidence and antibiotic susceptibility profiles bacterial pathogens isolated from CNS clinical specimens. In the routine clinical laboratory the majority of bacterial pathogens identified and tested are derived from the cerebrospinal fluid (CSF), most likely from patients with meningitis, and less commonly from brain abscesses, epidural abscesses or shunt/devices.

This study was undertaken to provide a current picture of bacterial pathogens commonly isolated from CSF and other CNS specimens by hospital laboratories participating in The Surveillance Network (TSN) Database USA during 2000--2002.

Methods
=======

TSN hospital laboratory and antimicrobial susceptibility testing methodology
----------------------------------------------------------------------------

TSN Database comprises a network of hospital laboratories throughout the USA. The number of participant hospitals that susceptibility test bacterial isolates from CNS specimens was 154 (2000), 155 (2001), and 153 (2002). Susceptibility data are collected onsite by each participating laboratory as a part of their routine diagnostic susceptibility testing. Methods used by these laboratories include predominantly VITEK (bioMérieux, St. Louis, MO) and MicroScan (Dade-Microscan, Sacramento, CA). TSN reflects current testing in participant laboratories and is the data reported to physicians from the respective laboratories. Only susceptibility data interpreted according to the recommendations established by the National Committee for Clinical Laboratory Standards (NCCLS) \[[@B7]\] are included in TSN. Bacterial isolates not tested for susceptibility to antimicrobial agents are not included in this database. In addition, TSN uses a series of quality-control filters (i.e., critical rule sets) to screen susceptibility test results for patterns indicative of testing error and removes suspect results from analysis for laboratory confirmation.

Bacterial species and antimicrobials tested
-------------------------------------------

We included only data on bacteria isolated from CNS clinical specimens, which comprised mostly isolates from CSF (most likely from patients with meningitis), but also isolates from brain abscesses, epidural abscess and shunt/devices. All specimens were isolated from patients during January 1, 2000 through December 31, 2002. Data were analyzed to determine the relative incidence and susceptibility to a core set of antimicrobial agents relevant to the treatment of CNS infections, as tested by participant clinical laboratories. For each organism only antibiotics for which susceptibility data were available were listed. Thus, drugs listed vary per organism. No susceptibility data for colistin for gram-negative organisms were available through TSN. MICs were interpreted as susceptible, intermediate, or resistant in TSN according to 2003 breakpoint criteria defined by the NCCLS \[[@B8]\]. TSN was not able to distinguish between community-acquired or hospital-acquired infection. In addition, TSN was not able to determine whether some isolates for which susceptibility data were requested, were actually contaminants and not true pathogens. Data available through TSN did not allow the identification of *H. influenzae*as encapsulated or as type b strains. No NCCLS interpretive breakpoints were defined for *N. meningitides*, so few laboratories susceptibility test this organism.

Results
=======

During the 3-year time period considered, a total of 6029 organisms were isolated and susceptibility tested (Table [1](#T1){ref-type="table"}). More than 90% of all organisms were derived from CSF, the remainder from brain or epidural abscess or shunt/device infections. The most common gram-positive isolates were *S. aureus*(23.7%), *S. pneumoniae*(11.0%), viridans group streptococci (VGS) (10.2%), and *Enterococcus*species (9.8%). *S. agalactiae*(2.2%), coagulase-negative staphylococci (shunt/device infections only) (3.1%), *Propionibacterium acnes*(2.0%) and *N. meningitidis*(1.0%) were comparatively rare. *E. coli*(5.0%), *Enterobacter cloacae*(4.3%), *Klebsiella pneumoniae*(2.5%) and *S. marcescens*(2.1%) were the most common *Enterobacteriaceae*. *Pseudomonas aeruginosa*(4.9%) was equally as common as *E. coli*. Although *N. meningitidis*comprised just 60/6029 isolates during the 3-year period the organism was likely under-represented because organisms included in this study were only those accompanied by a susceptibility test result. The modal age of patients was 1 or \<1 year for all organisms except for *P. acnes*(33 years), *N. meningitidis*(2 years) and *Corynebacterium*spp. (16 years). *H. influenzae*was rare. For enteric bacilli, staphylococcal, *P. aeruginosa*and *Acinetobacter*spp. a second smaller incidence peak, primarily with isolates derived from shunt infections and from CSF, was detected for patients \>65 years (data not shown).

###### 

Relative incidence of bacterial species isolated from central nervous system specimens. TSN Database USA 2000--2002.

  Organism                               Number of organisms   Percentage of total   Patient age range (year)   Modal Patient age (year)
  -------------------------------------- --------------------- --------------------- -------------------------- --------------------------
  *Staphylococcus aureus*                1426                  23.7                  \<1 -- \>90                \<1
  *Streptococcus pneumoniae*             661                   11.0                  \<1 -- \>90                1
  Viridans group streptococci            612                   10.2                  \<1 -- 88                  \<1
  *Enterococcus*spp.                     590                   9.8                   \<1 -- \>90                \<1
  *Escherichia coli*                     302                   5.0                   \<1 -- 89                  \<1
  *Pseudomonas aeruginosa*               295                   4.9                   \<1 -- \>90                \<1
  *Enterobacter cloacae*                 260                   4.3                   \<1 -- 84                  \<1
  Coagulase-negative staphylococci ^a^   184                   3.1                   \<1--\>90                  1
  *Acinetobacter baumannii*              162                   2.7                   \<1 -- 84                  \<1
  *Klebsiella pneumoniae*                151                   2.5                   \<1 -- 83                  \<1
  *Streptococcus agalactiae*             131                   2.2                   \<1 -- 83                  \<1
  *Serratia marcescens*                  127                   2.1                   \<1 -- 85                  \<1
  Proprionibacterium acnes               118                   2.0                   \<1 -- 82                  33
  *Enterobacter aerogenes*               103                   1.7                   \<1 -- 84                  \<1
  *Haemophilus influenzae*               75                    1.2                   \<1 -- \>90                \<1
  *Klebsiella oxytoca*                   62                    1.0                   \<1 -- 69                  \<1
  *Neisseria meningitidis*               60                    1.0                   \<1 -- 70                  2
  *Corynebacterium*spp.                  58                    1.0                   \<1 -- 87                  16
  Other ^b^                              652                   10.8                  \<1 -- \>90                \<1
  Total                                  6029                  100                                              

^a^Coagulase-negative staphylococci only includes isolates associated with shunt/device infections ^b^Organisms isolated at a frequency of \<0.5%.

Susceptibility of coagulase-positive or -negative staphylococcal species (shunt isolates only) was shown (Table [2](#T2){ref-type="table"}). *S. aureus*was the most common pathogen tested at all sites of infection. The proportion of *S. aureus*testing as MRSA using oxacillin as marker was 29.9%, 32.9%, 15.5% and 16.7% from CSF, brain abscess, shunt/device related or epidural abscess specimen sources, respectively. For coagulase-negative staphylococci 67.2% of isolates were oxacillin-resistant. Overall for all organisms, shunt isolates comprised \<2.0 % of all isolates isolated and tested from CNS sources during this time period, comprising mainly staphylococcal species. Parenteral cephalosporins were not active against MRSA but generally active against \>99% of oxacillin-susceptible isolates based on NCCLS breakpoints for non-CNS infections. All staphylococci were vancomycin susceptible. Low levels of resistance to gentamicin, chloramphenicol, trimethoprim-sulfamethoxazole and rifampin were detected, although resistance tended to be higher among coagulase-negative staphylococci.

###### 

Susceptibility of staphylococcal species isolated from cerebrospinal fluid, brain abscess, shunt related and epidural specimen sources. TSN Database USA 2000--2002.

                                                                            Cerebrospinal fluid   Brain abscess   Shunt related   Epidural abscess                                                    
  ------------------------------------------------------- ----------------- --------------------- --------------- --------------- ------------------ ------ ------ ----- ------ ------ ------- ------ ------
  *Staphylococcus aureus*                                 cefotaxime        270                   74.8            25.2            12                 75.0   25.0   10    90.0   10.0   NA^b^   NA     NA
                                                          ceftriaxone       273                   71.8            27.8            13                 76.9   23.1   18    88.9   11.1   NA      NA     NA
                                                          levofloxacin      666                   73.1            22.8            48                 72.9   27.1   33    97.0   3.0    83      79.5   18.1
                                                          chloramphenicol   277                   95.3            1.4             6                  100    0      9     88.9   0      NA      NA     NA
                                                          gentamicin        941                   93.0            6.8             65                 93.8   4.6    53    94.3   5.7    38      97.4   2.6
                                                          oxacillin         1189                  70.1            29.9            76                 67.1   32.9   71    84.5   15.5   108     83.3   16.7
                                                          rifampin          851                   96.9            2.5             51                 100    0      48    91.7   6.3    24      100    0
                                                          TMP-SMX^c^        1058                  95.9            4.1             72                 94.4   5.6    47    100    0      101     96.0   4.0
                                                          vancomycin        1150                  100             0               76                 100    0      58    100    0      102     100    0
  Coagulase-negative staphylococci (shunt-related only)   cefotaxime        ND^d^                 ND              ND              ND                 ND     ND     32    34.4   65.6   ND      ND     ND
                                                          ceftriaxone       ND                    ND              ND              ND                 ND     ND     37    35.1   64.9   ND      ND     ND
                                                          levofloxacin      ND                    ND              ND              ND                 ND     ND     75    82.7   5.3    ND      ND     ND
                                                          chloramphenicol   ND                    ND              ND              ND                 ND     ND     22    95.5   0      ND      ND     ND
                                                          gentamicin        ND                    ND              ND              ND                 ND     ND     124   75.8   22.6   ND      ND     ND
                                                          oxacillin         ND                    ND              ND              ND                 ND     ND     183   32.8   67.2   ND      ND     ND
                                                          rifampin          ND                    ND              ND              ND                 ND     ND     108   92.6   6.5    ND      ND     ND
                                                          TMP-SMX           ND                    ND              ND              ND                 ND     ND     114   77.2   22.8   ND      ND     ND
                                                          vancomycin        ND                    ND              ND              ND                 ND     ND     161   100    0      ND      ND     ND

^a^NCCLS interpretation for susceptible (S) and resistant (R) according to NCCLS guidelines \[[@B8]\]^b^NA -- \<5 organisms tested ^c^TMP-SMX -- Trimethoprim-sulfamethoxazole ^d^ND -- No data

Table [3](#T3){ref-type="table"} shows susceptibility for the other most common gram-positive organisms derived from CSF. VGS were isolated in significant numbers only from brain abscesses. For isolates from CSF specimens, resistance among enterococci varied by species. The prevalence of vancomycin resistance among *E. faecium*was 61.5% and the prevalence of resistance to ampicillin, the class representative for amino-penicillins, was 84.9%. Significantly less resistance was detected among *E. faecalis*isolates. Ceftriaxone resistance rates were recorded in 9.1% of VGS, 3.5% of *S. pneumoniae*, and 0% of *S. agalactiae*(data not tabulated), although more active than cefotaxime. Penicillin resistance was recorded in 5.3% of VGS, 16.6% of *S. pneumoniae*, and 0% of *S. agalactiae*(data not tabulated). For *S. pneumoniae*meropenem resistance was recorded in 7.9% of isolates but was not detected in other streptococcal species. Resistance to chloramphenicol among streptococci was uncommon (3--3.9%). Rifampin resistance ranged from 17.2% to 30.0% among enterococci and was not recorded among *S. pneumoniae*. TMP-SMX resistance was common among *S. pneumoniae*. Resistance in VGS from brain abscesses to ceftriaxone and penicillin was recorded as 3.0% and 1.4%, respectively, with organisms generally more susceptible than those isolated from CSF specimens. With the exception of a small number of VGS from CSF specimens, all streptococci were susceptible to levofloxacin.

###### 

Susceptibility of gram-positive organisms isolated from cerebrospinal fluid and brain abscess specimen sources. TSN Database USA 2000--2002.

                                                  Cerebrospinal fluid   Brain abscess                                     
  ----------------------------- ----------------- --------------------- --------------- ------------------ ------- ------ -----
  *Enterococcus faecalis*       ampicillin        229                   98.7            1.3                ND^b^   ND     ND
                                chloramphenicol   79                    79.7            15.2               ND      ND     ND
                                levofloxacin      136                   81.6            18.4               ND      ND     ND
                                penicillin        165                   99.4            0.6                ND      ND     ND
                                rifampin          58                    58.6            17.2               ND      ND     ND
                                vancomycin        239                   98.7            1.3                ND      ND     ND
  *Enterococcus faecium*        ampicillin        93                    15.1            84.9               ND      ND     ND
                                chloramphenicol   54                    92.6            0                  ND      ND     ND
                                levofloxacin      56                    12.5            85.7               ND      ND     ND
                                penicillin        50                    22.0            78.0               ND      ND     ND
                                rifampin          30                    56.7            30.0               ND      ND     ND
                                vancomycin        96                    38.5            61.5               ND      ND     ND
  Viridans group Streptococci   ampicillin        95                    62.1            6.3                10      90.0   0
                                cefotaxime        174                   85.1            9.8                32      96.9   3.1
                                ceftriaxone       220                   87.3            9.1                33      93.9   3.0
                                chloramphenicol   100                   96.0            3.0                14      92.9   0
                                meropenem         19                    100             0                  13      100    0
                                levofloxacin      90                    96.7            1.1                24      100    0
                                penicillin        437                   63.2            5.3                72      97.2   1.4
                                vancomycin        396                   100             \-^e^              44      100    0
  *Streptococcus pneumoniae*    cefotaxime        313                   80.5            7.7 (19.5 NS^c^)   ND      ND     ND
                                ceftriaxone       404                   85.4            3.5 (14.6 NS)      ND      ND     ND
                                chloramphenicol   180                   96.1            3.9 (3.9 NS)       ND      ND     ND
                                meropenem         76                    78.9            7.9 (21.1 NS)      ND      ND     ND
                                levofloxacin      283                   100             0                  ND      ND     ND
                                penicillin        565                   59.5            16.6 (40.5 NS)     ND      ND     ND
                                rifampin          70                    100             0                  ND      ND     ND
                                TMP-SMX^d^        233                   65.2            27.5 (34.8 NS)     ND      ND     ND
                                vancomycin        453                   100             \-                 ND      ND     ND

^a^NCCLS interpretation for susceptible (S) and resistant (R) according to NCCLS guidelines \[[@B8]\]^b^ND -- No data ^c^NS -- Percent non-susceptible (including intermediate and resistant isolates) ^d^TMP-SMX -- Trimethoprim-sulfamethoxazole ^e^Dashed line indicates that NCCLS breakpoints do not currently exist to interpret results as resistant

Susceptibility of predominant gram-negative species isolated from CSF specimens was shown (Table [4](#T4){ref-type="table"}). Gram-negative isolates were rarely isolated from brain abscess, shunt, or epidural abscess specimens. No meropenem resistance was detected in *Enterobacteriaceae*but detected in 10.3% and 23.5% of *P. aeruginosa*and *A. baumanii*. Resistance to amikacin was rare among *Enterobacteriaceae*and was 4.9% for *P. aeruginosa*and 17.9% for *Acinetobacter*spp. Among enteric organisms the prevalence of resistance was low against ceftriaxone for *E. coli*(0.6%), *E. aerogenes*(1.6%), and *K. pneumoniae*(2.8%) and were higher for *S. marcescens*(5.6%), *K. oxytoca*(13.3%), and *E. cloacae*(25.0%). Resistance to ceftazidime was 1.4% and 18.0 % in *E. coli*and *K. pneumoniae*, respectively. For *Enterobacteriaceae*, aztreonam resistance ranged from 1.5% in *E. coli*to 26.5% in *E. cloacae*. Levofloxacin resistance rates were uncommon in all *Enterobacteriaceae*tested apart from *K. pneumoniae*(9.2%). For *P. aeruginosa*the prevalence of ceftazidime and amikacin resistance was 11.0% and 4.9%, respectively and for *A. baumanii*38.7% and 17.9%, respectively. For both of these organisms relatively high resistance to levofloxacin was detected and meropenem was the most active β-lactam compound tested with resistance recorded as 10.3% and 23.5%, respectively. Approximately 24.0% of *H. influenzae*produced β-lactamase as estimated by ampicillin resistance. All *H. influenzae*isolates tested were susceptible to cefotaxime, ceftriaxone, and levofloxacin.

###### 

Susceptibility of gram-negative organisms isolated from cerebrospinal fluid specimen sources. TSN Database USA 2000--2002

  Organism                    Antimicrobial   Total n   %S^a^   %R
  --------------------------- --------------- --------- ------- -------
  *Escherichia coli*          amikacin        164       98.8    0
                              ampicillin      267       44.2    54.7
                              aztreonam       137       96.4    1.5
                              cefotaxime      168       98.2    0
                              ceftazidime     210       98.1    1.4
                              ceftriaxone     180       97.8    0.6
                              gentamicin      260       93.5    5.4
                              levofloxacin    198       97.5    2.5
                              meropenem       76        100     0
                              piperacillin    188       50.0    38.8
                              TMP-SMX^b^      252       77.0    23.0
  *Pseudomonas aeruginosa*    amikacin        184       92.9    4.9
                              aztreonam       133       67.7    15.0
                              cefotaxime      111       9.0     49.5
                              ceftazidime     236       80.1    11.0
                              ceftriaxone     116       6.0     61.2
                              gentamicin      251       80.9    11.2
                              levofloxacin    174       82.2    11.5
                              meropenem       97        84.5    10.3
                              piperacillin    198       82.8    17.2
                              TMP-SMX         128       0.8     99.2
  *Enterobacter cloacae*      amikacin        160       98.8    0
                              ampicillin      229       2.2     91.7
                              aztreonam       147       65.3    26.5
                              cefotaxime      154       63.6    28.6
                              ceftazidime     196       67.3    29.6
                              ceftriaxone     184       70.7    25.0
                              gentamicin      227       95.2    4.8
                              levofloxacin    176       96.0    4.0
                              meropenem       79        100     0
                              piperacillin    168       64.9    28.0
                              TMP-SMX         220       93.2    6.8
  *Acinetobacter baumannii*   amikacin        112       75.0    17.9
                              aztreonam       88        8.0     73.9
                              cefotaxime      102       21.6    54.9
                              ceftazidime     142       48.6    38.7
                              ceftriaxone     119       25.2    53.8
                              gentamicin      143       61.5    38.5
                              levofloxacin    106       53.8    43.4
                              meropenem       68        75.0    23.5
                              piperacillin    111       40.5    40.5
                              TMP-SMX         140       54.3    45.7
  *Klebsiella pneumoniae*     amikacin        95        92.6    0
                              ampicillin      129       0       98.4
                              aztreonam       70        84.3    14.3
                              cefotaxime      94        87.2    3.2
                              ceftazidime     111       76.6    18.0
                              ceftriaxone     108       84.3    2.8
                              gentamicin      131       87.8    8.4
                              levofloxacin    98        88.8    9.2
                              meropenem       47        100     0
                              piperacillin    102       65.7    26.5
                              TMP-SMX         133       83.5    16.5
  *Serratia marcescens*       amikacin        71        95.8    2.8
                              ampicillin      104       5.8     92.3
                              aztreonam       55        87.3    7.3
                              cefotaxime      70        80.0    8.6
                              ceftazidime     86        93.0    4.7
                              ceftriaxone     71        91.5    5.6
                              gentamicin      108       95.4    2.8
                              levofloxacin    80        98.8    1.3
                              meropenem       43        100     0
                              piperacillin    81        72.8    21.0
                              TMP-SMX         105       95.2    4.8
  *Enterobacter aerogenes*    amikacin        60        100     0
                              ampicillin      87        5.7     87.4
                              aztreonam       42        73.8    11.9
                              cefotaxime      54        74.1    1.9
                              ceftazidime     78        73.1    17.9
                              ceftriaxone     63        84.1    1.6
                              gentamicin      81        100     0
                              levofloxacin    51        100     0
                              meropenem       22        100     0
                              piperacillin    64        68.8    14.1
                              TMP-SMX         85        100     0
  *Haemophilus influenzae*    ampicillin      61        72.1    24.6
                              cefotaxime      27        100     \-^d^
                              ceftazidime     NA^c^     NA      NA
                              ceftriaxone     54        100     \-
                              levofloxacin    10        100     \-
                              TMP-SMX         32        87.5    9.4
  *Klebsiella oxytoca*        amikacin        37        100     0
                              ampicillin      52        3.8     86.5
                              aztreonam       34        76.5    17.6
                              cefotaxime      37        81.1    16.2
                              ceftazidime     44        81.8    18.2
                              ceftriaxone     45        84.4    13.3
                              gentamicin      51        96.1    3.9
                              levofloxacin    39        100     0
                              meropenem       23        100     0
                              piperacillin    38        73.7    21.1
                              TMP-SMX         51        80.4    19.6

^a^NCCLS interpretation for susceptible (S) and resistant (R) according to NCCLS guidelines \[[@B8]\]^b^TMP-SMX -- Trimethoprim-sulfamethoxazole ^c^NA \<5 organisms tested ^d^Dashed line indicates that NCCLS breakpoints do not currently exist to interpret results as resistant

Discussion
==========

Vaccination against infections with *H. influenzae*and *N. meningitidis*has significantly reduced the incidence of community-acquired infections caused by these organisms \[[@B9],[@B10]\]. Additionally, the growing use of the pneuococcocal conjugate vaccine has also had a positive impact on the incidence of pneumococcal meningitis \[[@B11],[@B12]\]. Since clinicians will likely initiate antimicrobial therapy prior to the microbiological characterization of the infecting agent, with the reduction in incidence of some species and increased resistance in others, resistance surveillance plays an important role in helping to understand trends in predominant pathogens and the impact of resistance on empiric choice \[[@B13]\]. The TSN database was not able to discriminate between specific diagnoses; however, considering bacterial pathogens isolated from specific specimen sources provides a contemporary picture of current susceptibility to commonly considered antimicrobial agents for the most prevalent organisms encountered at these sites of infections.

For the most significant community-acquired pathogens, this study showed similarities between epidemiological trends recently published. For meningitis in the USA, a report by Schuchat et al., 1997, recorded a significant shift from 15 months to 25 years, in the median age of patients with meningitis due to the five major pathogens: *H. influenzae*, *S. pneumoniae*, *N. meningitidis*, *S. agalactiae*, and *L. monocytogenes*\[[@B3]\]. Overall including all specimen sources together, although the majority of isolates were derived from the CSF, our study showed that isolates were derived from a wide spectrum of patient ages. However with few exceptions, the modal age of patients was ≤1 year old, demonstrating the burden of infection to be with infants and with a second peak for patients \>65 years \[[@B3]\].

The low comparative prevalence of *H. influenzae*indicates the success of the Hib vaccination program, which has largely removed this organism from its once ubiquitous role in meningeal infection in children in the United States \[[@B14]\]. Schuchat et al. also reported *L. monocytogenes*to be associated with infections in children \<1 year old and increases in incidence in patients older than 65 years. In this current study, the relative importance of both *L. monocytogenes*and *N. meningitidis*in infection cannot be measured since the organisms were rarely tested for antimicrobial susceptibilities in hospital laboratories and thus not reported through the system. Additionally, no NCCLS breakpoints have been defined for *N. meningitidis*\[[@B9]\]. Invasive pneumococcal disease is a significant cause of morbidity and mortality in the USA, especially for the young and old. Schuchat et al. demonstrated *S. pneumoniae*to infect patients of all ages, the same trend observed in our study. We also showed that with the exception of staphylococci, *S. pneumoniae*was the most common pathogen reported. A previous report showed 4.4% of cases of invasive pneumococcal disease associated with meningitis \[[@B3]\]. Further analysis of TSN showed that during the study period laboratories reported 661 non-repeat CNS pneumococcal isolates and 9868 non-repeat pneumococcal blood isolates, corresponding to a 6--7% rate of patients with invasive infections likely to be associated with pneumococcal meningitis, close to the 4--5% reported in 1995 \[[@B3]\]. This study also showed *Enterobacteriaceae*to be more common in hospital-acquired meningeal infections. *S. aureus*was by far the most frequently encountered pathogen in participant hospital laboratories, in this study together comprising 23.7% of isolates and the only isolate encountered at all specimen source sites considered. A previous French study showed *S. aureus*to be the most common pathogen associated with neurosurgical infections \[[@B15]\]. In addition to the staphylococci, *Enterococcus*spp., *P. aeruginosa*, *P. acnes*, and *Enterobacteriaceae*were most commonly isolated from infants (\<1 year old), although the median age also demonstrates the common involvement in adult patients. Together these organisms are becoming common causes of meningeal infection, often as a complication in immunocompromised patients, in patients with septicemia, following head trauma, or surgical procedures especially those involving CSF shunts.

The relatively high incidence of oxacillin-resistant *S. aureus*from CSF and brain abscesses negatively impacts the empiric utility of isoxazolyl penicillins reaffirming the need to include anti-MRSA coverage for patients with meningitis and brain abscesses, unless subsequent susceptibility testing shows the organism to be oxacillin susceptible. Even among isolates from shunts and epidural abscesses the 15--17% incidence of oxacillin resistance likely mandates the use of empiric therapies such as vancomycin that cover MRSA. However, it is important to note that these levels are lower than the national rates of MRSA of 51.2% (36,181/70,693) recorded among the general inpatient population in the USA during 2002 \[TSN Database USA, Focus Technologies Inc. Data on file\]. Susceptibility test results for MRSA to linezolid, a recently FDA-approved oxazolidinone-class antibiotic, and daptomycin, a recently approved glycopeptide-class antibiotic, were not available at the time of this study, although neither drugs have indications to treat infections of the central nervous system. Interestingly, despite an overall increase in the incidence of MRSA in hospitals in recent years in both inpatient and outpatient environments \[[@B16]\] an increased incidence of multi-drug susceptible MRSA, especially in community infections, has also been reported \[[@B17]\], which may augment the use of other compounds such as clindamycin in therapy. For shunt/device related infections, the high rates of oxacillin resistance recorded among coagulase-negative staphylococci indicate the need to consider appropriate therapies to cover these phenotypes. For both staphylococcal species resistance to rifampin, occasionally used in combination, was rare, comprising 0--6.5% of isolates from each species, respectively. Despite reports of vancomycin resistance in coagulase-negative staphylococci \[[@B18]\] and more recently *S. aureus*\[[@B19],[@B20]\], during the three-year study period, no vancomycin non-susceptible isolates of either species were recorded. Vancomycin also plays an important role in the treatment of other resistant gram-positive infections, most importantly those caused by penicillin-resistant *S. pneumoniae*(penicillin MIC \>2 μg/ml), for which no resistance was documented. Of the 661 isolates reported during the study period (11.0% of total), 16.6% and 23.9% tested as penicillin-resistant and -intermediate, respectively. For meningitis caused by pneumococci and in situations where the incidence of penicillin resistance is significant, the use of third-generation, parenteral cephalosporins such as ceftriaxone or cefotaxime is a more suitable empiric therapy. The percentage resistance to third-generation cephalosporins for the common streptococcal isolates from CSF, likely involved in meningeal infection, remained low (3.5% for ceftriaxone); however, concerns about resistance in CNS infections are sufficient to prompt recommendations to combine ceftriaxone or cefotaxime with vancomycin for empiric therapy of pneumococcal CNS infections. The reported rate of resistance in *S. pneumoniae*to ceftriaxone and cefotaxime reflects the higher breakpoints used compared to those used for non-meningeal pneumococcal isolates, reflecting the lower antibiotic concentrations achievable in the CNS. Importantly in addition to streptococci, 100% of *H. influenzae*tested as susceptible to ceftriaxone and cefotaxime. As such the utility of this drug class in community or hospital acquired infections meningeal infections with these organisms remains unchanged.

The incidence of vancomycin-resistant phenotypes among enterococci, organisms not commonly associated with meningeal infections, is alarming if the organisms isolated were colonizers. Importantly, the majority of glycopeptide-resistant isolates are *E. faecium*, which are less common than *E. faecalis.*

Our study showed resistance to amikacin remained very low (0--2.8%) among *Enterobacteriaceae*and low among *Acinetobacter*spp. and *P. aeruginosa*(17.9% and 4.9%, respectively), although the utility of this agent is limited in CNS infections. Importantly, bearing in mind their role in empiric therapy for meningitis, resistance to third-generation cephalosporins such as ceftriaxone, remained very uncommon in the common enterobacterial species (*E. coli*0.6%, *K. pneumoniae*2.6%, and *S. marcescens*5.2%). Resistance to ceftazidime in these species was somewhat higher than for ceftriaxone. Together these data suggest that the incidence of extended spectrum β-lactamases or AmpC β-lactamase producers still remains low, preventing a reliance on the use of carbapenems such as meropenem to which resistance among gram-negative organisms remains very rare. Changing patterns of antimicrobial resistance and the involvement of unusual species because of the increase in immunocompromised patients, has created renewed interest in drugs such as fluoroquinolones, which have previously been shown to have good potential for treating meningitis \[[@B21]\], although currently do not have an indication for use in CNS infection or in pediatrics. Nevertheless using levofloxacin as a marker for this drug class activity, streptococci, several species of *Enterobacteriaceae*and *H. influenzae*were highly susceptible using current breakpoint guidelines.

Conclusions
===========

Several factors influence the choice of antibacterial agent in the treatment of bacterial meningitis. Perhaps most importantly is the degree at which the agent is able to penetrate into the CSF, which to a large extent depends on the status of the blood brain barrier \[[@B22]\]. Low toxicity and rapid bactericidal activity are also important factors to consider and for these reasons β-lactams have always played a key role in treating infections of the CNS. Our study showed that for the treatment of the most important pathogens associated with acute community-acquired meningitis including *S. pneumoniae*, *H. influenzae*, and group B streptococci, while resistance to penicillin derivatives is relatively common, resistance to third-generation cephalosporins remains uncommon. Similarly, third-generation cephalosporins also retain good activity against the most common species of *Enterobactericeae*. For infections in which oxacillin-resistant staphylococcal species are suspected or shown microbiologically, vancomycin remains as a frontline agent to which no resistant isolates were detected through 2002. While national surveillance studies such as this are able to detect general trends in susceptibility, this information combined with local institutional level data play a critical role in choosing empiric therapies.
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